Click here to discover the largest collection of GeneMedi's Promise-ORF™ ORF/cDNA expression clones
- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected]
Protocol Library Download
 |
 |
Human LATS2/KPM ORF/cDNA clone-Adenovirus particle (NM_014572.3)
Cat. No.: vGMAD000587
Pre-made Human LATS2/KPM Adenovirus for LATS2 overexpression in-vitro and in-vivo. The LATS2 adenoviral vector excels as a vehicle for transient gene transfection in both stable cell lines and primary cells, including DC cells, macrophages, cardiomyocytes, hepatocytes, and neurons. The purified LATS2-encoding adenovirus also stands out as a quintessential tool for in vivo studies and vaccine research initiatives.
At GM Vector Core (GMVC), we provide bespoke adenovirus development and manufacture various grades of adenoviruses utilizing cutting-edge techniques. Dive deeper into our offerings.
Go to
LATS2/KPM products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
MSDS
Product information
| Catalog No. | Product Name | Adenovirus Grade | Adenovirus quantity |
| vGMAD000587 | Human LATS2 Adenovirus particle | Research Grade-In vitro | 1E+10PFU (1E+10pfu/ml×1ml) |
| 5E+10PFU (1E+10pfu/ml×5ml) | |||
| 1E+11PFU (1E+10pfu/ml×10ml) | |||
| Research Grade-In vivo | 1E+11PFU (1E+11pfu/ml×1ml) | ||
| GMP-like Grade | inquiry | ||
| GMP Grade | inquiry |
Product Description
| Catalog ID | vGMAD000587 |
| Gene Name | LATS2 |
| Accession Number | NM_014572.3 |
| Gene ID | 26524 |
| Species | Human |
| Product Type | Adenovirus particle (overexpression) |
| Insert Length | 3267 bp |
| Gene Alias | KPM |
| Fluorescent Reporter | Null |
| Mammalian Cell Selection | Null |
| Fusion Tag | 3xflag (C-Terminal) |
| Promoter | CMV |
| Resistance | Kanamycin |
| ORF Nucleotide Sequence | ATGAGGCCAAAGACTTTTCCTGCCACGACTTATTCTGGAAATAGCCGGCAGCGACTGCAAGAGATTCGTGAGGGGTTAAAACAGCCATCCAAGTCTTCGGTTCAGGGGCTACCCGCAGGACCAAACAGTGACACTTCCCTGGATGCCAAAGTCCTGGGGAGCAAAGATGCCACCAGGCAGCAGCAGCAGATGAGAGCCACCCCAAAGTTCGGACCTTATCAGAAAGCCTTGAGGGAAATCAGATATTCCTTGTTGCCTTTTGCTAATGAATCGGGCACCTCTGCAGCTGCAGAAGTGAACCGGCAAATGCTGCAGGAACTGGTGAACGCAGGATGCGACCAGGAGATGGCTGGCCGAGCTCTCAAGCAGACTGGCAGCAGGAGCATCGAGGCCGCCCTGGAGTACATCAGCAAGATGGGCTACCTGGACCCGAGGAATGAGCAGATTGTGCGGGTCATTAAGCAGACCTCCCCAGGAAAGGGGCTCATGCCAACCCCAGTGACGCGGAGGCCCAGCTTCGAAGGAACCGGCGATTCGTTTGCGTCCTACCACCAGCTGAGCGGTACCCCCTACGAGGGCCCAAGCTTCGGCGCTGACGGCCCCACGGCGCTGGAGGAGATGCCGCGGCCGTACGTGGACTACCTTTTCCCCGGAGTCGGCCCCCACGGGCCCGGCCACCAGCACCAGCACCCACCCAAGGGCTACGGTGCCAGCGTAGAGGCAGCAGGGGCACACTTCCCGCTGCAGGGCGCGCACTACGGGCGGCCGCACCTGCTGGTGCCTGGGGAACCCCTGGGCTACGGAGTGCAGCGCAGCCCCTCCTTCCAGAGCAAGACGCCGCCGGAGACCGGGGGTTACGCCAGCCTGCCCACGAAGGGCCAGGGAGGACCGCCAGGCGCCGGCCTCGCTTTCCCACCCCCTGCCGCCGGGCTCTACGTGCCGCACCCACACCACAAGCAGGCCGGTCCCGCGGCCCACCAGCTGCATGTGCTGGGCTCCCGCAGCCAGGTGTTCGCCAGCGACAGCCCCCCGCAGAGCCTGCTCACTCCCTCGCGGAACAGCCTCAACGTGGACCTGTATGAATTGGGCAGCACCTCCGTCCAGCAGTGGCCGGCTGCCACCCTGGCCCGCCGGGACTCCCTGCAGAAGCCGGGCCTGGAGGCGCCGCCGCGCGCGCACGTGGCCTTCCGGCCTGACTGCCCAGTGCCCAGCAGGACCAACTCCTTCAACAGCCACCAGCCGCGGCCCGGTCCGCCTGGCAAGGCCGAGCCCTCCCTGCCCGCCCCCAACACCGTGACGGCTGTCACGGCCGCGCACATCTTGCACCCGGTGAAGAGCGTGCGTGTGCTGAGGCCGGAGCCGCAGACGGCTGTGGGGCCCTCGCACCCCGCCTGGGTGCCCGCGCCTGCCCCGGCCCCCGCCCCCGCCCCCGCCCCGGCTGCGGAGGGCTTGGACGCCAAGGAGGAGCATGCCCTGGCGCTGGGCGGCGCAGGCGCCTTCCCGCTGGACGTGGAGTACGGAGGCCCAGACCGGAGGTGCCCGCCTCCGCCCTACCCGAAGCACCTGCTGCTGCGCAGCAAGTCGGAGCAGTACGACCTGGACAGCCTGTGCGCAGGCATGGAGCAGAGCCTCCGTGCGGGCCCCAACGAGCCCGAGGGCGGCGACAAGAGCCGCAAAAGCGCCAAGGGGGACAAAGGCGGAAAGGATAAAAAGCAGATTCAGACCTCTCCCGTTCCCGTCCGCAAAAACAGCAGAGACGAAGAGAAGAGAGAGTCACGCATCAAGAGCTACTCGCCATACGCCTTTAAGTTCTTCATGGAGCAGCACGTGGAGAATGTCATCAAAACCTACCAGCAGAAGGTTAACCGGAGGCTGCAGCTGGAGCAAGAAATGGCCAAAGCTGGACTCTGTGAAGCTGAGCAGGAGCAGATGCGGAAGATCCTCTACCAGAAAGAGTCTAATTACAACAGGTTAAAGAGGGCCAAGATGGACAAGTCTATGTTTGTCAAGATCAAAACCCTGGGGATCGGTGCCTTTGGAGAAGTGTGCCTTGCTTGTAAGGTGGACACTCACGCCCTGTACGCCATGAAGACCCTAAGGAAAAAGGATGTCCTGAACCGGAATCAGGTGGCCCACGTCAAGGCCGAGAGGGACATCCTGGCCGAGGCAGACAATGAGTGGGTGGTCAAACTCTACTACTCCTTCCAAGACAAAGACAGCCTGTACTTTGTGATGGACTACATCCCTGGTGGGGACATGATGAGCCTGCTGATCCGGATGGAGGTCTTCCCTGAGCACCTGGCCCGGTTCTACATCGCAGAGCTGACTTTGGCCATTGAGAGTGTCCACAAGATGGGCTTCATCCACCGAGACATCAAGCCTGATAACATTTTGATAGATCTGGATGGTCACATTAAACTCACAGATTTCGGCCTCTGCACTGGGTTCAGGTGGACTCACAATTCCAAATATTACCAGAAAGGGAGCCATGTCAGACAGGACAGCATGGAGCCCAGCGACCTCTGGGATGATGTGTCTAACTGTCGGTGTGGGGACAGGCTGAAGACCCTAGAGCAGAGGGCGCGGAAGCAGCACCAGAGGTGCCTGGCACATTCACTGGTGGGGACTCCAAACTACATCGCACCCGAGGTGCTCCTCCGCAAAGGGTACACTCAACTCTGTGACTGGTGGAGTGTTGGAGTGATTCTCTTCGAGATGCTGGTGGGGCAGCCGCCCTTTTTGGCACCTACTCCCACAGAAACCCAGCTGAAGGTGATCAACTGGGAGAACACGCTCCACATTCCAGCCCAGGTGAAGCTGAGCCCTGAGGCCAGGGACCTCATCACCAAGCTGTGCTGCTCCGCAGACCACCGCCTGGGGCGGAATGGGGCCGATGACCTGAAGGCCCACCCCTTCTTCAGCGCCATTGACTTCTCCAGTGACATCCGGAAGCAGCCAGCCCCCTACGTTCCCACCATCAGCCACCCCATGGACACCTCGAATTTCGACCCCGTAGATGAAGAAAGCCCTTGGAACGATGCCAGCGAAGGTAGCACCAAGGCCTGGGACACACTCACCTCGCCCAATAACAAGCATCCTGAGCACGCATTTTACGAATTCACCTTCCGAAGGTTCTTTGATGACAATGGCTACCCCTTTCGATGCCCAAAGCCTTCAGGAGCAGAAGCTTCACAGGCTGAGAGCTCAGATTTAGAAAGCTCTGATCTGGTGGATCAGACTGAAGGCTGCCAGCCTGTGTACGTGTAG |
| ORF Protein Sequence | MRPKTFPATTYSGNSRQRLQEIREGLKQPSKSSVQGLPAGPNSDTSLDAKVLGSKDATRQQQQMRATPKFGPYQKALREIRYSLLPFANESGTSAAAEVNRQMLQELVNAGCDQEMAGRALKQTGSRSIEAALEYISKMGYLDPRNEQIVRVIKQTSPGKGLMPTPVTRRPSFEGTGDSFASYHQLSGTPYEGPSFGADGPTALEEMPRPYVDYLFPGVGPHGPGHQHQHPPKGYGASVEAAGAHFPLQGAHYGRPHLLVPGEPLGYGVQRSPSFQSKTPPETGGYASLPTKGQGGPPGAGLAFPPPAAGLYVPHPHHKQAGPAAHQLHVLGSRSQVFASDSPPQSLLTPSRNSLNVDLYELGSTSVQQWPAATLARRDSLQKPGLEAPPRAHVAFRPDCPVPSRTNSFNSHQPRPGPPGKAEPSLPAPNTVTAVTAAHILHPVKSVRVLRPEPQTAVGPSHPAWVPAPAPAPAPAPAPAAEGLDAKEEHALALGGAGAFPLDVEYGGPDRRCPPPPYPKHLLLRSKSEQYDLDSLCAGMEQSLRAGPNEPEGGDKSRKSAKGDKGGKDKKQIQTSPVPVRKNSRDEEKRESRIKSYSPYAFKFFMEQHVENVIKTYQQKVNRRLQLEQEMAKAGLCEAEQEQMRKILYQKESNYNRLKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDTHALYAMKTLRKKDVLNRNQVAHVKAERDILAEADNEWVVKLYYSFQDKDSLYFVMDYIPGGDMMSLLIRMEVFPEHLARFYIAELTLAIESVHKMGFIHRDIKPDNILIDLDGHIKLTDFGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCRCGDRLKTLEQRARKQHQRCLAHSLVGTPNYIAPEVLLRKGYTQLCDWWSVGVILFEMLVGQPPFLAPTPTETQLKVINWENTLHIPAQVKLSPEARDLITKLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKQPAPYVPTISHPMDTSNFDPVDEESPWNDASEGSTKAWDTLTSPNNKHPEHAFYEFTFRRFFDDNGYPFRCPKPSGAEASQAESSDLESSDLVDQTEGCQPVYV |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
|---|---|---|
| Target Antibody | GM-Tg-g-T18390-Ab | Anti-LATS2 monoclonal antibody |
| Target Antigen | GM-Tg-g-T18390-Ag | LATS2 protein |
| ORF Viral Vector | pGMAD000587 | Human LATS2 Adenovirus plasmid |
| ORF Viral Vector | pGMLP-SPh-020 | Human LATS2 Lentivirus plasmid |
| ORF Viral Vector | pGMAP-SPh-160 | Human LATS2 Adenovirus plasmid |
| ORF Viral Vector | vGMAD000587 | Human LATS2 Adenovirus particle |
| ORF Viral Vector | vGMLP-SPh-020 | Human LATS2 Lentivirus particle |
| ORF Viral Vector | vGMAP-SPh-160 | Human LATS2 Adenovirus particle |
Target information
| Target ID | GM-T18390 |
| Target Name | LATS2 |
|
Gene Group Identifier （Target Gene ID in Homo species) |
26524 |
| Gene ID |
100050150 (Equus caballus), 101093824 (Felis catus), 26524 (Homo sapiens), 305922 (Rattus norvegicus) 477343 (Canis lupus familiaris), 50523 (Mus musculus), 508208 (Bos taurus), 699957 (Macaca mulatta) |
| Gene Symbols & Synonyms | LATS2,Lats2,KPM,4932411G09Rik |
| Target Alternative Names | 4932411G09Rik,KPM,Kinase phosphorylated during mitosis protein,LATS2,Large tumor suppressor homolog 2,Lats2,Serine/threonine-protein kinase LATS2,Serine/threonine-protein kinase kpm,Warts-like kinase |
| Uniprot Accession |
Q7TSJ6,Q9NRM7
Additional SwissProt Accessions: Q9NRM7,Q7TSJ6 |
| Uniprot Entry Name | |
| Protein Sub-location | Introcelluar Protein |
| Category | Therapeutics Target |
| Disease | cancer |
| Disease from KEGG | Hippo signaling pathway |
| Gene Ensembl | ENSECAG00000009862, ENSG00000150457, ENSCAFG00845021300, ENSMUSG00000021959,ENSMUSG00000114942, ENSBTAG00000014406, ENSMMUG00000019006 |
| Target Classification | Kinase, Tumor-associated antigen (TAA) |
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.